Year archive

NEUREN PHARMACEUTICALS LIMITED — 2025 filings

All 130 regulatory filings released by NEUREN PHARMACEUTICALS LIMITED (NEU) in 2025, sourced directly from the official regulator.

130 Filings

2025 Period

2025 filings (130)

Filing	Released	Lang
Health Canada approves Clinical Trial Application for Koala 2 pages 193.8KB Regulatory Filings	2025-12-21	English
FDA approves DAYBUE STIX (trofinetide), powder formulation 3 pages 220.3KB Regulatory Filings	2025-12-14	English
One-month administrative delay to FDA meeting for HIE 1 Regulatory Filings	2025-12-08	English
Application for quotation of securities - NEU 6 pages 18.9KB Share Issue/Capital Change	2025-11-23	English
Investor Presentation, 10 November 2025 23 pages 2.7MB Investor Presentation	2025-11-09	English
Record DAYBUE net sales of US$101.1 million in Q3 2025 3 pages 281.6KB Earnings Release Q3 2025	2025-11-05	English
Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid 2 pages 200.8KB Regulatory Filings	2025-10-19	English
Change of registered office in Australia 1 page 104 Regulatory Filings	2025-10-16	English
Application for quotation of securities - NEU 6 pages 18.8KB Share Issue/Capital Change	2025-10-02	English
Notification regarding unquoted securities - NEU 7 pages 21.3KB Share Issue/Capital Change	2025-09-21	English
Neuren partners with Hope for HIE to support NNZ-2591 2 pages 161.3KB Regulatory Filings	2025-09-08	English
Change of Director's Interest Notice 3 pages 201.2KB Director's Dealing	2025-09-07	English
Application for quotation of securities - NEU 6 pages 18.7KB Share Issue/Capital Change	2025-08-27	English
Half Yearly Report and Accounts 21 pages 398.3KB Interim / Quarterly Report H1 2025	2025-08-26	English
H1 2025 profit after tax A$15m, up from A$8m in H1 2024 4 pages 482.9KB Interim / Quarterly Report H1 2025	2025-08-26	English
Investor Presentation, 27 August 2025 22 pages 4.0MB Investor Presentation	2025-08-26	English
First site initiated for Neuren's PMS Phase 3 trial 2 pages 169.0KB Regulatory Filings	2025-08-24	English
Application for quotation of securities - NEU 6 pages 18.3KB Share Issue/Capital Change	2025-08-11	English
Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline 2 pages 169.2KB Regulatory Filings	2025-08-07	English
DAYBUE Q2 2025 net sales US$96.1 million up 14% from Q2 2024 3 pages 252.4KB Earnings Release Q2 2025	2025-08-06	English
Application for quotation of securities - NEU 5 pages 16.7KB Share Issue/Capital Change	2025-07-21	English
Change of Director's Interest Notice - J Pilcher 2 pages 209.0KB Director's Dealing	2025-07-21	English
Notification regarding unquoted securities - NEU 7 pages 21.2KB Share Issue/Capital Change	2025-07-08	English
Application for quotation of securities - NEU 5 pages 16.6KB Share Issue/Capital Change	2025-06-29	English
US patent allowed for NNZ-2591 to treat Pitt Hopkins 2 pages 197.9KB Regulatory Filings	2025-06-25	English
Notification of cessation of securities - NEU 4 pages 14.9KB Transaction in Own Shares	2025-06-24	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-06-15	English
Update - Notification of buy-back - NEU 6 pages 17.7KB Transaction in Own Shares	2025-06-15	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-06-12	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-06-11	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-06-10	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-06-09	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-06-05	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-06-04	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-06-03	English
Notification of cessation of securities - NEU 4 pages 14.9KB Transaction in Own Shares	2025-06-03	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-06-02	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-06-01	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-29	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-28	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-27	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-26	English
AGM Chair Address & CEO Presentation 25 pages 3.4MB Annual Report FY 2024	2025-05-26	English
Results of Meeting 1 page 9.5KB Declaration of Voting Results & Voting Rights Announcements	2025-05-26	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-25	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-22	English
Approval of long-term equity incentive 1 page 188.0 Capital/Financing Update	2025-05-22	English
Notification regarding unquoted securities - NEU 7 pages 22.0KB Share Issue/Capital Change	2025-05-22	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-21	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-20	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-19	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-18	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-15	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-14	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-13	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-12	English
NEU receives FDA minutes and re-confirms Phase 3 endpoints 2 pages 170.3KB Regulatory Filings	2025-05-12	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-11	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-08	English
DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024 3 pages 254.6KB Interim / Quarterly Report Q1 2025	2025-05-07	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-07	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-06	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-05	English
Notification of cessation of securities - NEU 4 pages 14.9KB Transaction in Own Shares	2025-05-05	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-04	English
Becoming a substantial holder 7 pages 757.1KB Major Shareholding Notification	2025-05-04	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-05-01	English
Neuren appoints Daryl DeKarske to executive team 1 Board/Management Information	2025-05-01	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-04-30	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-04-29	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-04-28	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-04-27	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-04-23	English
Notice of Annual General Meeting/Proxy Form 10 pages 1.1MB AGM Information	2025-04-23	English
Virtual AGM online guide 5 pages 315.9KB AGM Information	2025-04-23	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-04-22	English
Update - Notification of buy-back - NEU 6 pages 18.2KB Transaction in Own Shares	2025-04-21	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-04-16	English
Change of Director's Interest Notice - J Basile 2 pages 207.7KB Director's Dealing	2025-04-15	English
NEU confirms primary endpoints for Phase 3 trial in PMS 3 pages 176.5KB Regulatory Filings	2025-04-13	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-04-06	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-04-03	English
2024 Annual Report to shareholders 60 pages 2.0MB Annual Report FY 2024	2025-04-02	English
Appendix 4G 12 pages 375.0KB Regulatory Filings	2025-04-02	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-04-02	English
Notification of cessation of securities - NEU 4 pages 14.9KB Transaction in Own Shares	2025-04-02	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-04-01	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-31	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-30	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-27	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-26	English
Neuren initiates development of NNZ-2591 to treat HIE 2 pages 173.5KB Capital/Financing Update	2025-03-26	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-25	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-24	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-23	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-20	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-19	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-18	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-17	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-16	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-13	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-12	English
Becoming a substantial holder 5 pages 923.2KB Major Shareholding Notification	2025-03-11	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-11	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-10	English
Application for quotation of securities - NEU 5 pages 16.6KB Share Issue/Capital Change	2025-03-10	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-09	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-06	English
Notification of cessation of securities - NEU 4 pages 14.9KB Transaction in Own Shares	2025-03-06	English
Ceasing to be a substantial holder 3 pages 228.4KB Major Shareholding Notification	2025-03-05	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-05	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-04	English
Update - Notification of buy-back - NEU 6 pages 18.1KB Transaction in Own Shares	2025-03-03	English
Notification of cessation of securities - NEU 4 pages 14.8KB Regulatory Filings	2025-03-02	English
Appendix 4E and 2024 full year accounts 37 pages 398.4KB Annual Report FY 2024	2025-02-27	English
2024 results - A$166m comprehensive income for shareholders 7 pages 371.4KB Annual Report FY 2024	2025-02-27	English
Neuren receives DAYBUE sales milestone payment of US$50m 2 pages 223.5KB Capital/Financing Update	2025-02-27	English
2024 Full Year Results webinar 12 pages 1.3MB Earnings Release FY 2024	2025-02-27	English
DAYBUE (trofinetide) 2024 net sales US$348 million 2 pages 244.7KB Earnings Release FY 2024	2025-02-26	English
Neuren 2024 results investor webinar on 28 February 2025 1 Report Publication Announcement	2025-02-26	English
Becoming a substantial holder 5 pages 407.0KB Major Shareholding Notification	2025-02-24	English
Neuren receives Rare Pediatric Disease Designation from FDA 1 Regulatory Filings	2025-02-23	English
Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins 2 pages 226.9KB Regulatory Filings	2025-02-18	English
Type C Meeting granted by FDA for Phelan-McDermid syndrome 1 Regulatory Filings	2025-02-06	English
Priority Review Voucher sale proceeds received 1 pa Capital/Financing Update	2025-02-06	English
Neuren to present at autism research meeting 2 pages 274.7KB Regulatory Filings	2025-02-05	English
NEU Presentations at ACMG Annual Clinical Genetics Meeting 2 pages 283.8KB AGM Information	2025-01-21	English
J.P. Morgan Healthcare Conference recap 2 pages 168.7KB Regulatory Filings	2025-01-19	English
Neuren JP Morgan Healthcare Conference 2025 presentation 14 pages 1.6MB Investor Presentation	2025-01-15	English
Trofinetide marketing application submitted in Europe 2 pages 206.2KB Regulatory Filings	2025-01-14	English

Filings by year

2026 44 filings
2025 130 filings
2024 68 filings
2023 46 filings
2022 36 filings
2021 60 filings
2020 56 filings
2019 33 filings
2018 40 filings
2017 47 filings
2016 31 filings
2015 39 filings
2014 50 filings
2013 77 filings
2012 33 filings
2011 86 filings
2010 71 filings
2009 55 filings
2008 57 filings
2007 53 filings
2006 51 filings
2005 57 filings